Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03960541 Not yet recruiting - HIV Infections Clinical Trials

CD24Fc Administration to Decrease LDL and Inflammation in HIV Patients (CALIBER)

CALIBER
Start date: October 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2, randomized, single-blinded, placebo-controlled clinical trial. The intervention drug will be CD24Fc (IV infusion). A cohort of 64 patients with HIV on antiretroviral therapy will be randomized in a 1:1 fashion to be administered 7 doses of CD24Fc (240mg IV infusion) or placebo q2w during a 12-week window, followed by a 24-week follow-up window to assess the changes in LDL.

NCT ID: NCT03957369 Not yet recruiting - HIV Infection Clinical Trials

Primary Resistance in HIV Patients in Colombia

Start date: July 1, 2019
Phase:
Study type: Observational

We aim to determine the prevalence of pre-treatment of resistance-associated mutations (RAMs) in a naïve and recently diagnosed HIV infection in 18 centers from 12 cities in Colombia. This evaluation will include the genotyping of all three enzymes, reverse transcriptase, protease, and integrase. This type of complete primary resistance profile has not yet been reported in Colombia and there is only scanty data regarding resistance-associated mutations to NRTIs, NNRTIs, and PIs in the country

NCT ID: NCT03952520 Not yet recruiting - HIV Infections Clinical Trials

Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial

SNaPR01
Start date: February 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two implementation approaches [standard Intervention Mapping (IM) vs. tailored Intervention Mapping (TIM)] for scaling-up the evidence-based systems navigation and psychosocial counseling integrated intervention (SNaP) in HIV test sites in Vietnam.

NCT ID: NCT03945981 Not yet recruiting - HIV Infections Clinical Trials

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

Start date: May 27, 2019
Phase: Phase 3
Study type: Interventional

Early initiation of antiretroviral therapy (ART) reduces morbidity and mortality for individuals infected with HIV. Suppressing viral replication with ART also reduces the potential for transmission of HIV. Hence, ART is recommended for all persons with HIV viremia regardless of cluster of differentiation 4 (CD4) count. This is an open-label single arm which will evaluate the feasibility, efficacy and safety of a rapid Test and Treat model of care over 48 weeks using a fixed dose combination (FDC) of Dolutegravir (DTG) plus Lamivudine (3TC) as a first line regimen. Participants with newly diagnosed HIV-1 who are willing to start study treatment immediately following diagnosis will receive 50 milligram (mg) DTG + 300 (mg) 3TC FDC as first line therapy without waiting for screening laboratory results, at the Baseline/Day 1 Visit. The total duration for the study will be 52 weeks and 4 weeks of follow up period if required. This study will be conducted in United States (US) with approximately 120 participants.

NCT ID: NCT03934541 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

Start date: July 24, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.

NCT ID: NCT03930654 Not yet recruiting - HIV Infections Clinical Trials

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

IWPrEP
Start date: August 2019
Phase: N/A
Study type: Interventional

African American (AA) women are more vulnerable to HIV infection than other women. Truvada, when used as pre-exposure prophylaxis (PrEP), is one of the most effective approaches for HIV prevention; however, PrEP use among AA women remains low and has not responded to traditional interventions. This study proposes for the first time an innovative computer-based motivational intervention, increasing PrEP uptake (iPrEP), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.

NCT ID: NCT03928821 Not yet recruiting - HIV Infections Clinical Trials

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

Start date: June 19, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adults.

NCT ID: NCT03922269 Not yet recruiting - HIV Infections Clinical Trials

Trans People Living With HIV Throughout Europe

TIME
Start date: July 1, 2019
Phase:
Study type: Observational

The project will study a European cohort of individuals identifying themselves as transgender or non-binary and living with HIV. The study will collect both qualitative data on this cohort and clinical data over an 18 month period. The study will investigate the success of HIV treatment for this cohort through the primary outcome measure of HIV viral load recorded in routine blood tests. The results from this study will assist in informing future HIV treatment guidelines on the monitoring of HIV infection in transgender and non-binary individuals and assisting in the design of future interventional studies within this population.

NCT ID: NCT03922126 Not yet recruiting - HIV Infections Clinical Trials

Peer Intervention Latino Immigrant MSM

Start date: May 2019
Phase: N/A
Study type: Interventional

This study evaluates a peer intervention with HIV/STI self-testing kits to increase HIV/STI testing and PrEP uptake among Latino immigrant men who have sex with men. Half of participants will receive the "Listos" intervention (peer counseling, PrEP information, and HIV/STI testing kits) and half will receive the active control intervention (peer only group with no HIV/STI testing kits).

NCT ID: NCT03921723 Not yet recruiting - HIV Infections Clinical Trials

Dolutegravir Pediatric Liquid Formulation Study

Start date: April 22, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult subjects. The study will contain 6 periods with five prototype liquid formulations for evaluation in fasted state. In period 1, 2 and 3 single reference dose of 2 dispersible tablets of 5 milligram DTG will be administered and at least 2 liquid prototype DTG formulations (containing a target total dose of 10mg DTG). There will be a wash-out period of 7 days between each period. In period 4 through 6, there would be options to evaluate additional prototype liquid formulations. The total duration of study will be up to 17 weeks. DTG has been found to be safe and effective in adults infected with human immunodeficiency virus (HIV), and DTG liquid formulation are being developed for the treatment of HIV-infected pediatric subjects who weigh less than 25 kilograms (Kgs). Approximately 18 subjects will be enrolled in this study.